- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01050023
Provant Therapy of Venous Stasis Ulcer Trial
July 19, 2011 updated by: Southern California Institute for Research and Education
This pilot study hypothesizes that use of the Regenesis Provant Wound Therapy System (a radiofrequency device) twice daily over venous stasis ulcers (wounds thought to occur due to improper functioning of valves in the veins, usually of the legs) will result in increased rates of healing and a larger proportion of completely healed wounds after 12 weeks of therapy compared to wounds treated identically using a Provant device that is not activated to emit radiofrequency.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
25
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Long Beach, California, United States, 90822-5201
- VA Long Beach Healthcare System
-
Los Angeles, California, United States, 90073
- VA Greater Los Angeles Healthcare System
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Ulcer size between 1.0 and 16.0 cm2 at the time of randomization - measurements to be taken after sharp debridement if this is performed at the screening visit. Wounds must be free of necrotic tissue and fibrin slough after debridement with at least 90% of the surface covered with granulation tissue.
- Target ulcer must be present for at least 6 weeks prior to randomization. Other ulcers close to the study ulcer are allowable and may be any size but should be greater than 2cm away from the study ulcer; no more than 4 ulcers total on the target limb are allowed.
- A duplex ultrasound study documenting venous disease must be performed within on year of study entry. The ultrasound exam should document either chronic occlusion of the target limb popliteal, femoral, or iliac veins or the vena cava, or occlusion in the greater or lesser saphenous veins, or reflux in either the deep, saphenous, or perforating veins.
Exclusion Criteria:
- No ulcer on the target limb including the study ulcer may be deep enough to expose structures deep to the adipose lay of skin such as muscle, fascia, tendon, joint, or bone. The presence of sinus tracts that have not been sufficiently marsupialized such that the wound depth can be assessed by gross visual inspection is similarly exclusion.
- At the Screening or Randomization Visits, the presence of significant periwound cellulitis or the need to administer systemic antibiotics. system antibiotic therapy for any indication within 10 days of screening is an exclusion.
- Baseline arterial studies obtained within one year of screening or at the screening visit must show either an ankle-brachial index of the affected limb greater or equal to 0.75 based on the higher of the two pedal arteries systolic pressure measured with Doppler ultrasound compared to the ipsilateral brachial artery systolic pressure determined with Doppler ultrasound.
- Any major surgery or trauma affecting the target limb such as tibial fracture, knee arthroplasty, endovascular or open arterial or venous surgery or femoral stenting within 180 days of randomization.
- Participation in any clinical trial involving therapy for wound healing within 30 days of randomization.
- Concurrent administration of systemic agents that influence wound healing such as prednisone or dexamethasone in any quantity, cytotoxic chemotherapy agents, or immunosuppressive therapy.
- Previous ionizing radiation therapy at any dose near the wound bed (within 5 cm).
- A history of cancer in the target limb except for previous skin cancer treated in the target limb provided that a biopsy of the target wound is obtained within 90 days of randomization that confirms the absence of neoplasia.
- Severe renal failure - serum creatinine greater than 2.5 or subject on hemodialysis.
- Severe hepatic insufficiency: known cirrhosis, any degree of ascites, serum transamines more than three times the upper limit of normal.
- Known allergy or intolerance to cadexomeric iodine or latex free Profore bandages.
- The presence of 1) implanted pacemaker, automatic defibrillator, neurostimulator, bone stimulators, cochlear implants, or other devices with metal leads; 2) implanted or programmable pumps or intravenous or intrathecal drug delivery; 3) metal implant within 25 cm of area of treatment.
- Pregnancy. Women of childbearing potential must agree to use adequate contraception.
- Live expectancy of last than one year.
- Uncompensated or uncontrolled right heart failure with associated edema.
- Inability to walk independently (adaptive devices such as walkers or canes are allowed).
- BMI greater than 50.
- Severe anemia, hemoglobin less than 8.5
- Poorly controlled diabetes, A1cHgb greater than 12
- Severe hypoalbuminemia, serum albumen less than 2.6.
- Active local or systemic malignancy such as lung cancer or leukemia
- Severe hypertension - systolic bp greater than 180 or diastolic bp greater than 100
- Severe hypoxemia - chronic oxygen or ventilator therapy.
- HIV infection unless on retroviral therapy and viral load undetectable by PCR.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1 - Active Treatment
Provant device activated to emit RF energy
|
Twice daily application of the active Provant device to the wound for twelve (12) weeks.
|
Sham Comparator: 2 - Inactive Treatment
Provant device not activated to emit RF energy
|
Twice daily application of the inactive Provant device to the wound for twelve (12) weeks.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Rates of wound closure (measured as change in surface area - mm2/day)
Time Frame: during and after 12 weeks of therapy
|
during and after 12 weeks of therapy
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Proportion of wounds achieving complete healing
Time Frame: afer 12 weeks of therapy
|
afer 12 weeks of therapy
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2009
Primary Completion (Anticipated)
November 1, 2011
Study Completion (Anticipated)
November 1, 2011
Study Registration Dates
First Submitted
January 13, 2010
First Submitted That Met QC Criteria
January 13, 2010
First Posted (Estimate)
January 15, 2010
Study Record Updates
Last Update Posted (Estimate)
July 20, 2011
Last Update Submitted That Met QC Criteria
July 19, 2011
Last Verified
July 1, 2011
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- #965
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Venous Stasis Ulcers
-
HealthpointTerminatedUlcer | Venous Ulcer | Venous Stasis UlcerGermany, Poland, Belgium, Czech Republic, Hungary
-
Integra LifeSciences CorporationTerminatedVenous Stasis UlcerPuerto Rico
-
Merakris TherapeuticsUS Department of Veterans AffairsRecruitingVenous Leg Ulcer | Venous Stasis UlcerUnited States
-
PEMF Systems, Inc.Henry Ford Health SystemTerminatedVenous Stasis UlcersUnited States
-
HealthpointCompleted
-
Erchonia CorporationTerminatedVenous Stasis UlcerUnited States, France
-
West Penn Allegheny Health SystemThe Cleveland Clinic; Tactile Systems Technology, Inc.Terminated
-
PolarityTEProfessional Education and Research InstituteCompletedVenous Leg Ulcer | Venous Stasis | Venous Stasis UlcerUnited States
-
HealthpointCompletedVenous Leg Ulcer | Venous Stasis UlcersUnited States, Canada
-
Tactile MedicalCompletedVenous Insufficiency | Venous Leg Ulcer | Chronic Venous Insufficiency | Venous Ulcer | Venous Stasis UlcerUnited States
Clinical Trials on Provant Device (Wound Therapy System)
-
Regenesis Biomedical, Inc.CompletedPost-Operative Pain Following Total Knee ArthroplastyUnited States
-
Regenesis Biomedical, Inc.CompletedDiabetic Neuropathy PeripheralUnited States
-
Regenesis Biomedical, Inc.CompletedDiabetic Peripheral NeuropathyUnited States
-
Regenesis Biomedical, Inc.CompletedOsteoarthritis, KneeUnited States
-
Regenesis Biomedical, Inc.Completed
-
Regenesis Biomedical, Inc.Completed
-
Regenesis Biomedical, Inc.WithdrawnPostoperative PainUnited States
-
Regenesis Biomedical, Inc.TerminatedDiabetic Foot UlcersUnited States
-
Brigham and Women's HospitalCenter for Integration of Medicine & Innovative Technology; Fogarty International...Completed
-
DeRoyal Industries, Inc.Lincoln Memorial UniversityCompletedSkin Sensitisation | Skin Reaction to Mechanical, Thermal and Radiation StimuliUnited States